-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 I6k4nxtL4qAFmi8leB3dzl5Srz0SqRUdQGLTSx2krX47ggRFlB0gHlYfyHuzc9DC
 snlEgKEYo5EUPPE2inWk1g==

<SEC-DOCUMENT>0000891836-07-000373.txt : 20071218
<SEC-HEADER>0000891836-07-000373.hdr.sgml : 20071218
<ACCEPTANCE-DATETIME>20071218171704
ACCESSION NUMBER:		0000891836-07-000373
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20071218
FILED AS OF DATE:		20071218
DATE AS OF CHANGE:		20071218
EFFECTIVENESS DATE:		20071218

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KONINKLIJKE PHILIPS ELECTRONICS NV
		CENTRAL INDEX KEY:			0000313216
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTRONIC & OTHER ELECTRICAL EQUIPMENT (NO COMPUTER EQUIP) [3600]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-05146-01
		FILM NUMBER:		071313921

	BUSINESS ADDRESS:	
		STREET 1:		BREITNER CENTER
		STREET 2:		AMSTELPLEIN 2
		CITY:			AMSTERDAM
		STATE:			P7
		ZIP:			1096 BC
		BUSINESS PHONE:		31 20 59 77777

	MAIL ADDRESS:	
		STREET 1:		BREITNER CENTER
		STREET 2:		AMSTELPLEIN 2
		CITY:			AMSTERDAM
		STATE:			P7
		ZIP:			1096 BC

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PHILIPS ELECTRONICS N V
		DATE OF NAME CHANGE:	19930727

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PHILIPS NV
		DATE OF NAME CHANGE:	19910903
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>sc0167.htm
<DESCRIPTION>SCHEDULE 14A
<TEXT>
<HTML>
<HEAD>
<TITLE>Schedule 14A
</TITLE>
</HEAD>
<BODY><H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549</FONT></H1>

<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=3>SCHEDULE 14A </FONT></H1>

<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Proxy Statement
Pursuant to Section 14(a) of the Securities<BR>
Exchange Act of 1934 (Amendment No.&nbsp;&nbsp;&nbsp;) </FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Filed by the Registrant [&nbsp;&nbsp;&nbsp;]<BR>
Filed by a Party other than the Registrant [X] </FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Check the appropriate box:<BR>
[&nbsp;&nbsp;&nbsp;]&nbsp;&nbsp;Preliminary Proxy Statement<BR>
[&nbsp;&nbsp;&nbsp;]&nbsp;&nbsp;<B>Confidential, For Use of the Commission Only (as Permitted by Rule 14a-6(e)(2))</B><BR>
[&nbsp;&nbsp;&nbsp;]&nbsp;&nbsp;Definitive Proxy Statement<BR>
[&nbsp;&nbsp;&nbsp;]&nbsp;&nbsp;Definitive Additional Materials<BR>
[X]&nbsp;&nbsp;Soliciting Material Pursuant to &sect;240.14a-12 </FONT></P>

<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2><U>Visicu, Inc.</U><BR>
(Name of Registrant as Specified In Its Charter)<BR><BR>

________________________________________________________<BR>
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)</FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Payment of Filing Fee (Check the
appropriate box):<BR>
[X] No fee required. <BR>
[&nbsp;&nbsp;&nbsp;] Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. </FONT></P>

          <TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
               <TR VALIGN=TOP>
               <TD ALIGN=RIGHT WIDTH=3%></TD>
               <TD WIDTH=97%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
&nbsp;&nbsp;&nbsp;1)&nbsp;&nbsp;Title of each class of securities to which transaction applies: </FONT><BR><BR></TD>
               </TR>
               <TR VALIGN=TOP>
               <TD ALIGN=RIGHT WIDTH=3%></TD>
               <TD WIDTH=97%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
&nbsp;&nbsp;&nbsp;2)&nbsp;&nbsp;Aggregate number of securities to which transaction applies: </FONT><BR><BR></TD>
               </TR>
               <TR VALIGN=TOP>
               <TD ALIGN=RIGHT WIDTH=3%></TD>
               <TD WIDTH=97%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;3)&nbsp;&nbsp;
               Per unit price or other underlying value of transaction computed pursuant to
               Exchange Act Rule 0-11 (set forth the amount on which the filing fee is
               calculated and state how it was determined): </FONT><BR><BR></TD>
               </TR>
               <TR VALIGN=TOP>
               <TD ALIGN=RIGHT WIDTH=3%></TD>
               <TD WIDTH=97%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;4)&nbsp;&nbsp;
Proposed maximum aggregate value of transaction: </FONT><BR><BR></TD>
               </TR>
               <TR VALIGN=TOP>
               <TD ALIGN=RIGHT WIDTH=3%></TD>
               <TD WIDTH=97%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;5)&nbsp;&nbsp;
               Total fee paid: </FONT></TD>
               </TR>
               </TABLE>
               <BR>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>[&nbsp;&nbsp;&nbsp;] Fee paid previously with
preliminary materials. </FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>[&nbsp;&nbsp;&nbsp;] Check box if any part of the fee
is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which
the offsetting fee was paid previously. Identify the previous filing by registration
statement number, or the Form or Schedule and the date of its filing. </FONT></P>

<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
               <TR VALIGN=TOP>
               <TD ALIGN=RIGHT WIDTH=3%></TD>
               <TD WIDTH=97%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;1)&nbsp;&nbsp;
          Amount Previously Paid: </FONT><BR><BR></TD>
               </TR>
               <TR VALIGN=TOP>
               <TD ALIGN=RIGHT WIDTH=3%></TD>
               <TD WIDTH=97%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;2)&nbsp;&nbsp;
          Form, Schedule or Registration Statement No.:</FONT><BR><BR></TD>
               </TR>
               <TR VALIGN=TOP>
               <TD ALIGN=RIGHT WIDTH=3%></TD>
               <TD WIDTH=97%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;3)&nbsp;&nbsp;
          Filing Party: </FONT><BR><BR></TD>
               </TR>
               <TR VALIGN=TOP>
               <TD ALIGN=RIGHT WIDTH=3%></TD>
               <TD WIDTH=97%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;4)&nbsp;&nbsp;
          Date Filed: </FONT><BR><BR></TD>
               </TR>
                </TABLE>

<PAGE>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Royal Philips Electronics
(&#147;Philips&#148;) issued the following press release on December 18, 2007: </FONT></P>

<P ALIGN=RIGHT>
<IMG SRC="philips.jpg">
</P>
<P>
<IMG SRC="pr.jpg">
</P>
<BR><BR>
<P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>December 18, 2007 </FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2><B>PHILIPS ANNOUNCES INTENTION TO
ACQUIRE US-BASED VISICU &#150; A LEADER IN CLINICAL IT FOR THE INTENSIVE CARE UNIT</B>
</FONT></P>

<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
<TR VALIGN=TOP>
     <TD WIDTH=3%>&#149;</TD>
     <TD WIDTH=3%></TD>
     <TD WIDTH=84%><FONT FACE="Times New Roman, Times, Serif" SIZE=2><I>Philips to
pay USD 12.00 for each VISICU share, representing an acquisition price of
approximately USD 430 million (approximately EUR 290 million)</I></FONT></TD>
</TR>
<TR VALIGN=TOP>
     <TD WIDTH=3%>&#149;</TD>
     <TD WIDTH=3%></TD>
     <TD WIDTH=84%><FONT FACE="Times New Roman, Times, Serif" SIZE=2><I>Philips
to grow business by combining VISICU&#146;s clinical IT hardware and software
for the ICU with Philips&#146; patient monitoring products to help medical staff
actively and remotely monitor more ICU patients, boosting hospital productivity
and patient care</I></FONT></TD>
</TR>
<TR VALIGN=TOP>
     <TD WIDTH=3%>&#149;</TD>
     <TD WIDTH=3%></TD>
     <TD WIDTH=84%><FONT FACE="Times New Roman, Times, Serif" SIZE=2><I>Deal
complements Philips&#146; earlier acquisition of clinical IT company Emergin </I></FONT></TD>
</TR>
<TR VALIGN=TOP>
     <TD WIDTH=3%>&#149;</TD>
     <TD WIDTH=3%></TD>
     <TD WIDTH=84%><FONT FACE="Times New Roman, Times, Serif" SIZE=2><I>VISICU&#146;s
Board of Directors will recommend offer to shareholders</I></FONT></TD>
</TR>
</TABLE>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2><B>Amsterdam, the Netherlands and
Baltimore, Maryland </B>&#150; Royal Philips Electronics (NYSE:PHG, AEX:PHI) today
announced a merger agreement with clinical IT and service provider VISICU Inc. (NASDAQ:
EICU) through which Philips is offering to acquire the entire share capital of VISICU for
USD 12.00 per VISICU share. By integrating VISICU&#146;s remote patient monitoring and
clinical decision support technology with Philips&#146; patient monitors, both companies
expect to accelerate growth by offering products that provide more effective clinical
decision support to hospital staff, while allowing them to monitor far greater numbers of
critically ill patients. The board of directors of VISICU has approved the transaction and
has recommended that VISICU shareholders vote their shares in favor of the merger. </FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Based in Baltimore, Maryland, VISICU
is a leader in clinical IT systems that enable critical care medical staff to actively
monitor patients in hospital intensive care units (ICUs) from remote locations. The
company&#146;s patented clinical IT system, called the eICU Program, provides real time,
24x7 patient monitoring in ICUs, and can be likened to an air-traffic controller&#146;s
station by centrally networking critical care physicians and nurses to ICU beds using
voice and video. Equipped with artificial intelligence algorithms, the system also offers
advance clinical support. The eICU Program has been shown to significantly reduce patient
mortality, length of stay, and medical complications while lowering ICU costs. </FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Philips&#146; cash offer represents
an enterprise value of approximately USD 300 million (approximately EUR 200 million), when
accounting for approximately USD 130 million in cash on VISICU&#146;s balance sheet as of
September 30, 2007. Closing of the merger is subject to the terms and conditions of the
merger agreement, the approval of VISICU&#146;s shareholders, and to customary regulatory
clearance. The transaction is expected to close in the first quarter of 2008. </FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>In commenting on the transaction,
Steve Rusckowski, CEO of Philips Healthcare said: &#147;Today&#146;s deal builds on
Philips&#146; announcement two weeks ago that we&#146;re acquiring another clinical IT
company, Emergin. Philips is a market leader in patient monitoring systems in the
hospital, so we know the challenges our customers face &#150; rising patient numbers,
staff shortages and concerns about patient safety. By investing in clinical IT solutions
like those offered by VISICU and Emergin, we believe we can offer customers more
attractive patient monitoring solutions that improve hospital productivity as well as
patient outcomes. So making these investments we believe will drive further growth in our
patient monitoring business.&#148; </FONT></P>

<PAGE>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>VISICU&#146;s eICU Program can track
ICU patients at various hospitals, and provides continuous monitoring of patient vitals
signs, medications, labs and early-warning alarms &#150; known as &#145;Smart Alerts&#146;
&#150; which are triggered by deviations in a patients&#146; vital signs based on their
admitting or current diagnosis. &#145;Smart Alerts&#146; use embedded algorithms and
protocols to send warning signals to physicians and nurses to provide early medical
intervention and optimal care. The eICU Program also supplements hospitals&#146; critical
care staff by allowing them to increase the number of ICU patients monitored by a factor
of 15. The clinical and financial benefits of the eICU Program have resulted in several
affiliated hospitals electing to expand their eICU program to serve smaller regional and
rural hospitals outside of their network. </FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Commenting on today&#146;s
announcement, VISICU chairman and CEO, Frank T. Sample said: &#147;At VISICU, we have a
long and successful track record of developing innovative solutions to enhance the
delivery of patient care within the ICU resulting in significant improvements in clinical
outcomes and saving more lives. We&#146;re excited to be teaming up with Philips &#150; a
global leader in patient monitoring &#150; as it will give us the opportunity to build on
Philips&#146; extensive market presence to grow beyond our current focus on the ICU and US
market. As a result the Board will recommend approving the merger to our
shareholders.&#148; </FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Founded in 1998, VISICU has a staff
of approximately 100, which includes clinicians, software developers, sales and client
services personnel. The company had sales over a 12-month period ending in the third
quarter of 2007 of approximately USD 36 million and earnings before interest, taxes,
depreciation and amortization of approximately USD 9 million. Over the last three years,
VISICU has seen it sales almost double, and the company reported in its third quarter
results that it had approximately USD 60 million in revenue backlog. </FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Upon completion of the acquisition,
Philips intends to capitalize on its extensive sales channel network to accelerate
VISICU&#146;s adoption by ICUs at US hospitals, while internationalizing VISICU&#146;s
activities and migrating its technologies into other departments within the hospital.
Philips believes leveraging VISICU&#146;s and Emergin&#146;s clinical IT capabilities will
also accelerate growth in its existing patient monitoring business. Philips has a leading
position in the global patient monitoring market, which in 2006 was estimated to be
approximately EUR 2 billion or approximately USD 3 billion. </FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>To view the December 4 announcement:
<I>&#147;Philips to acquire US-based clinical IT company Emergin&#148;</I>, please
<U>click here</U>. </FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>For more information, please contact:<BR>
Jayson Otke<BR>
Philips Corporate Communications<BR>
Tel: +31 20 59 77215<BR>
Email: jayson.otke@philips.com </FONT></P>

<P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Andre Manning<BR>
Philips Healthcare<BR>
Tel: +1 646 508 4545<BR>
Email: andre.manning@philips.com</FONT></P>

<P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Robert Pepper<BR>
VISICU, Inc.<BR>
Tel: +1 410 246 5364<BR>
Email: rpepper@visicu.com </FONT></P>

<PAGE>
<P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>About Royal Philips
Electronics<BR>
Royal Philips Electronics of the Netherlands (NYSE: PHG, AEX: PHI) is a global
leader in healthcare, lighting and consumer lifestyle, delivering products,
services and solutions through the brand promise of &#147;sense and
simplicity&#148;. Headquartered in the Netherlands, Philips employs
approximately 128,100 employees in more than 60 countries worldwide. With sales
of EUR 27 billion in 2006, the company is a market leader in medical diagnostic
imaging and patient monitoring systems, energy efficient lighting solutions,
personal care and home appliances, as well as consumer electronics. News from
Philips is located at www.philips.com/newscenter. </FONT></P>

<P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>About Visicu<BR>
VISICU, Inc. (NASDAQ: EICU) is a healthcare information technology and clinical
solutions company focused on transforming the delivery of critical care through
its eICU&reg; Program. Through remote monitoring technology and clinical
intelligence, experienced critical care resources are leveraged to provide
coverage and early intervention for safer, more effective patient care.
Currently more than 180 hospitals serving over 250,000 patients annually have
partnered with VISICU to implement eICU programs. More information is available
at www.VISICU.com. VISICU&reg; and eICU&reg; are registered trademarks of
VISICU, Inc. All rights reserved. All other brand names, product names, company
names, trademarks and service marks are the property of their respective owners.
visicu-g </FONT></P>

<P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Forward-looking statements<BR>
This release may contain certain forward-looking statements with respect to the
financial condition, results of operations and business of Philips and certain
of the plans and objectives of Philips with respect to these items. By their
nature, forward-looking statements involve risk and uncertainty because they
relate to events and depend on circumstances that will occur in the future and
there are many factors that could cause actual results and developments to
differ materially from those expressed or implied by these forward-looking
statements. </FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>IMPORTANT ADDITIONAL INFORMATION WILL
BE FILED WITH THE SEC VISICU intends to mail to its stockholders and file with the
Securities and Exchange Commission (the &#147;SEC&#148;) a Proxy Statement in connection
with the proposed transaction, and to file other relevant materials with the SEC. The
Proxy Statement and other materials filed with the SEC will contain important information
about VISICU, Philips, the merger and related matters. Investors and security holders are
urged to read the Proxy Statement carefully when it is available. Investors and security
holders will be able to obtain free copies of the Proxy Statement and other documents
filed with the SEC by VISICU and Philips through the web site maintained by the SEC at
www.sec.gov. In addition, investors and security holders will be able to obtain free
copies of the Proxy Statement from VISICU at www.VISICU.com under the Company/Investor
Relations section or by contacting Vince Estrada, Senior Vice President and Chief
Financial Officer, in the Investor Relations department at (410) 843-4530 or at
vestrada@visicu.com. VISICU and its directors and executive officers also may be deemed to
be participants in the solicitation of proxies from the stockholders of VISICU in
connection with the transaction described herein. Information regarding the special
interests of these directors and executive officers in the transaction described herein
will be included in the Proxy Statement described above. Additional information regarding
these directors and executive officers is also included in VISICU&#146;s proxy statement
for its 2007 Annual Meeting of Stockholders, which was filed with the SEC on or about
April 30, 2007. This document is available free of charge at the SEC&#146;s web site at
www.sec.gov and from VISICU by contacting Vince Estrada in the Investor Relations
department at (410) 843-4530 or at vestrada@visicu.com, or on VISICU&#146;s web site at
www.VISICU.com under the Company/Investor Relations section. </FONT></P>

<P>*****************************************</P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Visicu, Inc. (&#147;Visicu&#148;)
intends to mail to its stockholders and file with the Securities and Exchange Commission
(the &#147;SEC&#148;) a Proxy Statement in connection with the proposed transaction, and
to file other relevant materials with the SEC. WE URGE INVESTORS AND SECURITY HOLDERS TO
CAREFULLY READ THE PROXY STATEMENT AND OTHER MATERIALS FILED WITH THE SEC IN CONNECTION
WITH THE PROPOSED TRANSACTION OR INCORPORATED BY REFERENCE IN THE PROXY STATEMENT, BECAUSE
THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT VISICU, PHILIPS, THE PROPOSED TRANSACTION
AND RELATED MATTERS. Investors and security holders will be able to obtain free copies of
the Proxy Statement and other documents filed with the SEC by Visicu and Philips through
the web site maintained by the SEC at www.sec.gov. In addition, investors and security
holders will be able to obtain free copies of the Proxy Statement from Visicu at
www.visicu.com under the Company/Investor Relations section or by contacting Vince
Estrada, Senior Vice President and Chief Financial Officer, in the Investor Relations
department at (410) 843-4530 or at <U>vestrada@visicu.com</U>. </FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Visicu and its directors and
executive officers also may be deemed to be participants in the solicitation of proxies
from the stockholders of Visicu in favor of the proposed transaction. Information
regarding the special interests of these directors and executive officers in the proposed
transaction will be included in the Proxy Statement described above. Additional
information regarding these directors and executive officers is also included in
Visicu&#146;s proxy statement for its 2007 Annual Meeting of Stockholders, which was filed
with the SEC on or about April 30, 2007. This document is available free of charge at the
SEC&#146;s web site at www.sec.gov and from Visicu by contacting Vince Estrada in the
Investor Relations department at (410) 843-4530 or at vestrada@visicu.com, or on
Visicu&#146;s web site at www.visicu.com under the Company/Investor Relations section. </FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>philips.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 philips.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"``C`*@#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#G[^\NC?W0
M-S-@2OUD/J:LW&E>(-/MQ>3V>HP0X!\YD<*,],GM6?J'_'_=_P#75_YFOI1;
MBTMO#<<]^\:6BVR^:9?N[=HR#ZYZ8[U][F..>"C3Y8*7-_P-CYO"X98ASO*U
MCQCPK\1-5T2^CCU"ZFO=.8@2),Q=XQ_>5CSQZ=#[=:[GXM7#IX2L9;>9E#7R
M8>-\9!CD[CM7BCE-S%`0F>`>H%>J^/8Y8OA5X;CF!$J-;*X/4$0/G-88W"48
M8VA5@K-NS\S3#UYRP]2$G>R,SX2W5Q/XON%EN)9%%BYP[DC.^/UKNOB;))%X
M&NWC=D8218920?OBO&O#?B.[\+ZF]_91022O"82)@2N"5.>".?E%:^O?$75O
M$6D2Z;=VMDD,C*Q:)'##:01U8CM2Q665JF80KQ2Y4U^&XZ.,IQPSIR>NI)\-
MKNYE\=V"27,SH5ERK2$C_5M7H/Q6EDA\'JT4CQM]JC&48@]&]*\X^&?_`"/V
MG_[LO_HMJ]$^+7_(F+_U]Q_R:N;,(K^UJ*MV_-FF%;^I3?K^2.*^%EU<S>-%
M26XFD7[-(<.Y([>M=C\7II8/"UFT4KQL;]1E&(./+D]*XGX4?\CLO_7M)_2N
MR^,7_(J67_7^O_HN2C&17]L4U;M^HZ#?U&;]3FOA)=7$WBVY6:XED46+D!W)
M&?,C]:]HKQ+X/_\`(WW7_7@__HR.O;:\W/TEC';LCJRQWPZOW9\Y>*[V[3Q=
MK"I=3JHO)0`)&`'S'WKW+P<S/X-T=G8LQM(R23DGBO!_%O\`R.&L_P#7Y+_Z
M$:]V\&?\B7HW_7I'_*O0SN*6"HV\OR.;+FW7J?UU/"O$MW<CQ5K*BYF"B^G`
M`D.`/,:HFTK7X;%=0:SU!;5D$@N`C[=I&0V1T'O2>)?^1LUK_K_G_P#1C5[[
MX;FBM_!&CS3R)'$FG0,[NP"J/+7))/05Z.-QSP5"E*,$[V_(Y:&'6(J33E:Q
MXQX;\?ZSH-VGG74U[9$CS()G+G'^P3RI]NGK7K?BSQ;%H?A-=6L]LSW01;0D
M?*Q<;@Q]@H)_3C->!ZD]M)JMX]FNVT:>1H%QC$98[1CZ8KTC6M%OK[X/:++'
M&TDEH!.R#D^40V"![`J?IFL,RP6&E6HU9+EYG9]+]=?R^9IA,154*D$[V6AY
M_-<ZSXDU#]X]YJ-V^6"*&<CUPHZ#Z#`K<\,Z!KFG^+-)FN-)OX8A=1[Y&@<*
M!N'4XP/QK(\/>)+_`,,W[7FGF(LZ;'65-RLN<]B#V[&O3M$^+MA=RI!JUHUD
MS''GHV^,>YZ%1^==683Q5*#A0I)PMTW^[_*YCA8T9R4JDVI7_K4](HI%8,H9
M2"I&01T-%?`GTI\MWW_(0NO^NS_^A&M%M$\37RQA]+U>=,#RR]O*R@=L$C`%
M=9=?"+7Y[F>1;S30LCLPS+)G!.?[E>Q6<+6]E!"Y!:.-4)'3(&*^TQN=TJ,8
M.A:;_(\##Y?.HY>TO$\B\(_"^^GOHKS7XEM[6-@PMB0SRD=`V.`OKW[8'6NA
M^,7_`"*=E_U_I_Z+DKT*N6\>^&KSQ3HEO96,L$<D=TLQ,[$#:$=>P/.6%>)3
MS*>(QM.MB'9)_)'H2PD:6'E"DM6>6?#71]/USQ-/:ZE;+<0+9O($8D88.@!X
M([$_G77^/_"&@:/X0N;RPTV."X1XPKAV)`+@'J?2K'@3P%JOA?7I;^]N+.2)
M[9H0(78MDLA[J./E-=-XST.Y\1>&9]-M'B2:1T8-,2%^5@3T!/;TKLQ>8IYC
M"5.I[EXWU=O,PH86V%:E#WM?4\?^&?\`R/VG_P"[+_Z+:O1/BU_R)B_]?<?\
MFK+\'_#C6/#_`(GM=2N[FQ>&(.&6)W+<J0,94#OZUU7CGP]=^)O#XL+*2".4
M3K)F9B%P`?0'UHQN+H3S.E5C).*M=_-AAZ%2.$G!K5W/+_A1_P`CLO\`U[2?
MTKLOC%_R*EE_U_K_`.BY*A\$_#[5O#?B)=0O+BRDA$+QXA=RV3CU4>E;_CWP
MU>>*=$M[*QE@CDCNEF)G8@8".O8'G+"C%8NA/-*=:,ERJVOWA1H5(X.4&M=3
MS+X7ZG8Z5XGN)[^[AMHFLG0/*P4%MZ''UP#^5>R6'B+1M4N?L]CJ=K<S;2VR
M*0,<#J<?C7DW_"G_`!!_S^:9_P!_9/\`XBND\#_#_5?#/B$ZA>W%E)$8'CQ"
M[ELDJ>ZCCBJS6.!Q#E7C5]ZVB%@GB*5J;AIW/-/%O_(X:S_U^2_^A&O=O!G_
M`")>C?\`7I'_`"K@-<^%NN:GKVH7T-UIZQ7%P\J!Y'#`$Y&<)UKTKP_I\NE>
M'M/T^=D:6W@6-S&25)`[9`K/-\71K82E"G*[5K_<5@:-2G6G*2LG_F?//B7_
M`)&S6O\`K_G_`/1C4Y=(\1WUK"!INK7%N54P_N)63;C@KQC&.A%=OK'PJUS4
M-;U"]BN].6.YN99D#R/D*SDC/R=>:]1T2RDTW0=.L9F1I;:UBA<H25+*H!QG
MMQ7H8G.J5"C#V-I/\M#FI9?.I4E[2Z1Y#X8^%VIW]W'/K41L[%2&:)F'FRCT
MP/NCU)P?0=QZ]J&IZ=H5I%+>SQVMN6$2$C"@X.!QTX!]JO5S'CKP[>>)]!CL
M;*2".5;A929F(7`##L#SS7@5<;+'XB/UF5H^70]*&'6&I/V2N_S,C6-/^'.L
M*\LU_I,,S`DRVMVD;Y]2`<,?J#7C6HQ6D.HW,=A.UQ:+(1#*Z[2Z]B1_^KZ"
MNW_X4_X@_P"?S3/^_LG_`,15[2O@]=_;5;5[^W%JIR4M2S,_MD@;?KS_`%KZ
M'"8G"8.+OB')=M_N/,KT:^(:_=<K[G>^!6F?P/I!FSN^S@#/]T$A?_'<45O0
MPQV\$<$*+'%&H1$48"J!@`45\=6FJE24TK7;9[D(\L5'L/HHHK,L****`"BB
DB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`/_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>pr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pr.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0`617AI9@``24DJ``@```````````#_
MVP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+#!D2$P\4'1H?'AT:'!P@)"XG("(L
M(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_VP!#`0D)"0P+#!@-#1@R(1PA,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C+_P``1"``G`,P#`2(``A$!`Q$!_\0`'P```04!`0$!`0$```````````$"
M`P0%!@<("0H+_\0`M1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A
M!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%
M1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9
MFJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?H
MZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!`0$!`0````````$"`P0%!@<("0H+
M_\0`M1$``@$"!`0#!`<%!`0``0)W``$"`Q$$!2$Q!A)!40=A<1,B,H$(%$*1
MH;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::G
MJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W
M^/GZ_]H`#`,!``(1`Q$`/P#WSC'2CBE[5YS=:[XTO_&>MZ/X?71%M]+^SY:_
M64.WFQ[NJ'!Y#=AVZT4Z4IMM65E=OYI?J#=CT0X`S2]ZX;2_$&O67B.ST#Q3
M:Z>D]_%++9W6GR.8W9-I:(HPR"%RVXD#&`.:[GM2E!Q>O75/OT!.X^BBBF`4
M49HS0`F**2N6_P"$@N_^%D_\(WLA^Q_V3]NW[3YGF>=LQG.-N/;.>]))N]N@
M-V.JHHK-U;4X](TB\U&97:.UA>>14`+%54L0,D#.!ZTDFVDMV!HTO:N)\&ZO
MXKUQ8]3U:UTNUTB[A,MI#`[M<*"04WD_(04R>,'D<#D#M.!]:J2<6T]T"=T/
MHHHH`****`"BBB@!,<TF*IV5[;WT#36\F]%EDB)P1\Z.48<^C*1^%0:+J1U?
M2H;[[%>67F[O]'O(O+E3#$?,N3C.,CV(I<K6K6P7-6BC-%,`HHHH`8>`*\FB
M_P"$J_X6GXQ_X1G^R?\`ER^T?VEYO_/#Y=FS_@6<^U>L_P`-<KHWA^[T_P`:
M>)=8F>%K?5/LODJCDNOE1E6W`C`Y/&"?PK6A44%.]M59)][I_D)J]BAI?A[7
M[OQ'9Z]XHNM.>?3XI8K2UT^.0(C/M#2%V.2Q7*[2",8(YKG/#^EZYXMU+Q'%
M>>)=2M-,M-9N8XELKADG+@C"ESG;$JXPB]2Q)Z"O7,<XKE_!^@7>@?VZ+MX7
M^WZM/?1>42=L;[<!L@?-P<XR/>G&L^5WM>R2TVUOH#6J/-=;\0/:>((_"FO>
M,;_3K#1X8Q+>VZN+O4)6C#`[D0A%4-C!R3CDL3N5^A>+)H-8OM"\-^);S7DU
M"SF?3VO48W%M=I&2H9Y0JE&VDC@@$`$#DMW.N>&-77Q"?$7AJ^MK74)(A#<V
MEW$3;W8!^5G*88,H)PW)X5>!G->'2/'FIM+%JNL:7IL1@EB4:5"[L[.C*'+N
M0R%&VL-IYY!(XKI]K1<%IT[JU^]K=_,GEE?^O\SC?"^LP7/B.TM[_P`4>)].
M\1"6%IK+5"!;3R-\TD:Q8PH89"YVD;T*@D8IFMZO+;^*KVW\8ZYXKTA&NYDL
M9K!Q%:FV'S)]Q27;YL$@$C*AL8.-^?PAXW\2:?%HGBF\T.;3S*LDUW!&YNAM
M;=\F55%8CY,XX4G@][EUHOQ!AO=4M[74-$U'1[F1VB@U5)"R1N6+1D*.5^8K
M\Q8848"CBB]+FZ;=_P`4[?@PUL=OI3'^R+-GO1?.84+7:*`LYVC]X`O`#=>.
M.:Y3_FN__<N?^W-;GA/08_"_AFST>*=YUM@096`!9F8LQP.@RQP.<#')ZU7_
M`.$?N_\`A9'_``DN^'['_9/V+9N/F>9YV_.,8VX]\Y[5QIQ4G9W6R?<JS:1S
M$5EJWB/XB^+M.;Q'JMAIMNMIB&SE"L&:,-E'8$QC*MD*!NW<GC!QKVTU.?1/
M&WAR^U_4KB'08Q=6]P)=LTR20R/Y,S<^8G0$<9]A@#O]&\/7=AXR\2ZQ,\+6
MVJ?9?(5&)=?+C*MN!&!R>,$_A6=<>$-0EU#QS,LUN$U^TC@M06;*,L+1DO\`
M+P,L.F>*Z55BF[6LDK:=5:_ZBL_S,&TN;SPK\*]#CTR_N)M4UIK6"SDO7\V.
MVDFC7@?W8U"L5&&P<<$9K6F\#:W!!)?Z?XUUIM:"EP;B96M&D(YS#M(53DX`
MSMR",XK2G\(&_P#`.G^'KFY\B[L[:!8[R`9,,\2KB1"<'J#TP2"1D9K,GTKX
MCWT+Z5<:UHUO:.IB.I6T,OVHJ!PX3(16;'."-N25.0*A34M4TG>[N@M;=&1K
MGBW5]:\">#]8TJ<VM]?:K!"REFCB>3]XK(X4DF(NO3))7'>M#4_"VK:!HNKZ
MU_PE^M7,Z:9=--'+*!$TICR'C4#]T%()`7D<`,`"&T]5\$EM&\,:5HYBCM]'
MU*WN7\WY2Z1[MQ^5<%V)R>`"236_XDLIM6\,:GIL!19KNTE@C:0D*&="H)P"
M<9/I2E5CHHVM=^MO,=GU/.GT/79/AU;>)SXRUL:E;Z6EXB^8HA(5?-"O&!\Y
MQ\I9B23R<CY:DO\`3-=OO!(\8'Q;JL6I)8?VA'!;E8[50`91'Y0'S``[,LS$
M]3D?+78_\(_=_P#"M_\`A&]\/VS^R?L._)\OS/)V9SC.W/MG':C_`(1^[_X5
MM_PC>^'[9_9/V'?N/E^9Y.S.<9VY]LX[4_:^F_9!;\CD]:U(W^C:3K'B#Q?+
MH6EW6FP3K;Z:_ES2W+<NRG:SE`'0;1NZY.-N3)X+NKW6SXG\-_VIK<5K9&)+
M:\N_DOU60,6RSKD`E25)4,%8="!M1_!'B73M1T#5M'DT::^L-(CTV1+]9"B,
MG62-E&<G+#G'&>N[BYX;\*^+]-\9:AK&I:IITEMJ'ERW2V\;;W9(V58E!&%1
M2_WLEF\M<XW-6J=/DEJKVT];K]+DV=S+^$/AK_BF-)UW^VM7_P"6_P#H`NO]
M%^_(G^KQ_P`"Z_>YJ+1_%&KVWP@T62&Z>?6]3O#86]S=,90DCS2`.Y))PJJ<
M<-R%X(K8\&^&_&/AT6&CRWFDR:!9RS%GB607$R-YA4$$%1\SJ2`>-N,GG,NE
M_#^?_A6EKX8U"[2&_MF::&\M<L8)?-9T="P!!&0#C!P6`(SFBK4A*4I-IW::
M]-?^`-)VMY?Y#9O`VN0P27NG^-M9;60I=6N)E:T:0CG,.TA5.3@#.W((SBLC
M7/%.I>(_`GA'4--O9M+N]0U:WMY98A@!_P!XC_)N.Y-ZY"L>0!FM>?2?B/?0
MOI,^LZ+;VCJ8CJ5O#+]J*@<.$R$5FQS@C;DE3D"KFJ>"-VD^&-,T<Q16^C:E
M;W+F7Y2Z1[MQ^5<%V)R>`"2362FE9R:;3NM-+>>G]:C:?0Q=7LM6\&^(-#U.
MW\2:K?1:GJ<=C=6NH2"2(K*2=R*H41E=IQ@=P.`"#Z@<^M<OXOT"[U_^POLC
MPI]@U:"]E\TD;HTW9"X!^;D8S@>]=1BL*CYDGH.*LV24445(!1110`4444`%
J%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`'__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
